Zetagen Therapeutics

United States - Syracuse, New York

• 14/08/2023
• Series B
• $9,790,000

Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016.

This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet™, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable™ and ancillary osteologic treatments including, ZetaFuse™, ZetaSet™, ZetaDent™ and ZetaBase™. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.

Related People

Joe LoyFounder

United States - Dallas, Texas

Experienced Executive with a distinguished career in building and leading teams in rapid growth organizations within the Spine & Orthopedic industries. Joe has played key roles in Initial Public Offerings, (IPO), Merger & Acquisitions, (M&A), and National Distribution Agreements with such companies as Stryker/CoAlign, NuVasive, Pfizer/Leibinger, and US Surgical. He also serves as an Advisor & Board of Director for a variety of Spine & Orthopedic implant companies.

LinkedIn https://www.linkedin.com/in/joe-loy-09160333/